{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:54:27Z","timestamp":1785426867618,"version":"3.56.0"},"reference-count":78,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Viral replication and transmissibility are the principal causes of endemic and pandemic disease threats. There remains a need for broad-spectrum antiviral agents. The most common respiratory viruses are endemic agents such as coronaviruses, respiratory syncytial viruses, and influenza viruses. Although vaccines are available for SARS-CoV-2 and some influenza viruses, there is a paucity of effective antiviral drugs, while for RSV there is no vaccine available, and therapeutic treatments are very limited. We have previously shown that probenecid is safe and effective in limiting influenza A virus replication and SARS-CoV-2 replication, along with strong evidence showing inhibition of RSV replication in vitro and in vivo. This review article will describe the antiviral activity profile of probenecid against these three viruses.<\/jats:p>","DOI":"10.3390\/v14030612","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T03:36:23Z","timestamp":1647401783000},"page":"612","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-9956","authenticated-orcid":false,"given":"Ralph A.","family":"Tripp","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA"},{"name":"TrippBio, Inc., Jacksonville, FL 32256, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-5983","authenticated-orcid":false,"given":"David E.","family":"Martin","sequence":"additional","affiliation":[{"name":"TrippBio, Inc., Jacksonville, FL 32256, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.virol.2004.10.048","article-title":"Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening","volume":"332","author":"Towner","year":"2005","journal-title":"Virology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19443","DOI":"10.1038\/s41598-021-98219-x","article-title":"Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening","volume":"11","author":"Work","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"646676","DOI":"10.3389\/fphar.2021.646676","article-title":"Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen","volume":"12","author":"Rodon","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Choi, R., Zhou, M., Shek, R., Wilson, J.W., Tillery, L., Craig, J.K., and Van Voorhis, W.C. (2021). High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity. PLoS ONE, 16.","DOI":"10.1101\/2021.01.21.427657"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Postnikova, E., Cong, Y., Dewald, L.E., Dyall, J., Yu, S., Hart, B.J., Zhou, H., Gross, R., Logue, J., and Cai, Y. (2018). Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194880"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2025866118","DOI":"10.1073\/pnas.2025866118","article-title":"Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing","volume":"118","author":"He","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Geraghty, R., Aliota, M., and Bonnac, L. (2021). Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses, 13.","DOI":"10.3390\/v13040667"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e00487-17","DOI":"10.1128\/JVI.00487-17","article-title":"Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase","volume":"91","author":"Abdelnabi","year":"2017","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of Favipiravir to Treat Lassa Virus Infection in Macaques","volume":"24","author":"Rosenke","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin\u2014current status of a broad spectrum antiviral agent","volume":"2","author":"Snell","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1093\/cid\/ciz835","article-title":"Respiratory Syncytial Virus Infection Morbidity in the Elderly: Time for Repurposing of Ribavirin?","volume":"70","author":"Kerstjens","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/v4112786","article-title":"Arenaviruses and Lethal Mutagenesis. Prospects for New Ribavirin-based Interventions","volume":"4","author":"Moreno","year":"2012","journal-title":"Viruses"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/13543784.2020.1735349","article-title":"Emerging small and large molecule therapeutics for respiratory syncytial virus","volume":"29","author":"Bergeron","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/13543776.2021.1928637","article-title":"A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013\u2013present)","volume":"31","author":"Schols","year":"2021","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"704205","DOI":"10.3389\/fphar.2021.704205","article-title":"The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107930","DOI":"10.1016\/j.pharmthera.2021.107930","article-title":"Drug repurposing for COVID-19: Approaches, challenges and promising candidates","volume":"228","author":"Ng","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug repurposing approach to fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101529","DOI":"10.1016\/j.jbc.2021.101529","article-title":"Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir","volume":"298","author":"Gordon","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1093\/cid\/ciab528","article-title":"Global Respiratory Syncytial Virus\u2013Related Infant Community Deaths","volume":"73","author":"Mazur","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/irv.12557","article-title":"Burden and epidemiology of influenza- and respiratory syncytial virus-associated severe acute respiratory illness hospitalization in Madagascar, 2011\u20132016","volume":"13","author":"Rabarison","year":"2019","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/irv.12486","article-title":"Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness","volume":"12","author":"Rolfes","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bergeron, H.C., and Tripp, R.A. (2021). Immunopathology of RSV: An Updated Review. Viruses, 13.","DOI":"10.3390\/v13122478"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tripp, R., and Stambas, J. (2021). Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins. Viruses, 13.","DOI":"10.3390\/v13040625"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.15585\/mmwr.mm7104e2","article-title":"COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence\u201425 U.S. Jurisdictions, April 4-December 25, 2021","volume":"71","author":"Johnson","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMc2102507","article-title":"Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons","volume":"385","author":"Kissler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bonilauri, P., and Rugna, G. (2021). Animal Coronaviruses and SARS-COV-2 In Animals, What Do We Actually Know?. Life, 11.","DOI":"10.20944\/preprints202101.0002.v1"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.coviro.2021.10.012","article-title":"New preventive strategies for respiratory syncytial virus infection in children","volume":"51","author":"Glowinski","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-0031-1283282","article-title":"Respiratory Syncytial Virus Infection in Adults","volume":"32","author":"Walsh","year":"2011","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1968","DOI":"10.1002\/rmv.1968","article-title":"Molecular epidemiology of respiratory syncytial virus","volume":"28","author":"Pangesti","year":"2018","journal-title":"Rev. Med Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00008480-199402000-00004","article-title":"Respiratory syncytial virus infection in children","volume":"6","author":"Muncie","year":"1994","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1093\/cid\/ciab509","article-title":"Deaths Attributed to Respiratory Syncytial Virus in Young Children in High\u2013Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS)","volume":"73","author":"Blau","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.15585\/mmwr.mm705152a3","article-title":"Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19\u2014Six Hospitals, United States, July\u2013August 2021","volume":"70","author":"Wanga","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6908a1","article-title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2020\u20132021 Influenza Season","volume":"69","author":"Grohskopf","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/AITC202111160","article-title":"Influenza","volume":"174","author":"Uyeki","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jama.2021.24282","article-title":"A National Strategy for the \u201cNew Normal\u201d of Life With COVID","volume":"327","author":"Emanuel","year":"2022","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100794","DOI":"10.1016\/j.drup.2021.100794","article-title":"An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment","volume":"59","author":"Rosik","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00044-021-02841-3","article-title":"Review on molnupiravir as a promising oral drug for the treatment of COVID-19","volume":"31","author":"Zarenezhad","year":"2022","journal-title":"Med. Chem. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-021-00202-8","article-title":"A tale of two antiviral targets\u2014and the COVID-19 drugs that bind them","volume":"21","author":"Cully","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e00388-21","DOI":"10.1128\/mSystems.00388-21","article-title":"Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches","volume":"6","author":"Cakir","year":"2021","journal-title":"mSystems"},{"key":"ref_42","first-page":"45716","article-title":"Generation of RNAi Libraries for High-Throughput Screens","volume":"2006","author":"Clark","year":"2006","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/ph6020124","article-title":"siRNA Genome Screening Approaches to Therapeutic Drug Repositioning","volume":"6","author":"Perwitasari","year":"2013","journal-title":"Pharmaceuticals"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1440-1711.2005.01332.x","article-title":"Genome-wide screening for gene function using RNAi in mammalian cells","volume":"83","author":"Cullen","year":"2005","journal-title":"Immunol. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/978-1-61779-037-9_25","article-title":"RNAi Screening in Mammalian Cells to Identify Novel Host Cell Molecules Involved in the Regulation of Viral Infections","volume":"Volume 721","author":"Coyne","year":"2011","journal-title":"Antiviral RNAi"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1096\/fj.11-193466","article-title":"Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens","volume":"26","author":"Meliopoulos","year":"2011","journal-title":"FASEB J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ymeth.2015.07.002","article-title":"A Genome-wide RNAi screening method to discover novel genes involved in virus infection","volume":"91","author":"Panda","year":"2015","journal-title":"Methods"},{"key":"ref_48","first-page":"001603","article-title":"Discovering antiviral restriction factors and pathways using genetic screens","volume":"102","author":"Jones","year":"2020","journal-title":"J. Gen. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Todd, K.V., and Tripp, R.A. (2020). Vero Cells as a Mammalian Cell Substrate for Human Norovirus. Viruses, 12.","DOI":"10.3390\/v12040439"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100045","DOI":"10.1016\/j.jvacx.2019.100045","article-title":"Gene-edited vero cells as rotavirus vaccine substrates","volume":"3","author":"Murray","year":"2019","journal-title":"Vaccine X"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Murray, J., Todd, K.V., Bakre, A., Orr-Burks, N., Jones, L., Wu, W., and Tripp, R.A. (2017). A universal mammalian vaccine cell line substrate. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188333"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"170021","DOI":"10.1038\/sdata.2017.21","article-title":"Development of improved vaccine cell lines against rotavirus","volume":"4","author":"Wu","year":"2017","journal-title":"Sci. Data"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Orr-Burks, N., Murray, J., Todd, K.V., Bakre, A., and Tripp, R.A. (2021). Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0259129"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.1038\/s41598-021-97658-w","article-title":"Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro","volume":"11","author":"Murray","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/AAC.01532-12","article-title":"Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy","volume":"57","author":"Perwitasari","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejmech.2017.04.070","article-title":"Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus","volume":"135","author":"Tonelli","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1152\/physrev.00025.2013","article-title":"The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective","volume":"95","author":"Nigam","year":"2015","journal-title":"Physiol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by Organic Anion Transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11095-006-9181-4","article-title":"Organic Anion Transporters of the SLC22 Family: Biopharmaceutical, Physiological, and Pathological Roles","volume":"24","author":"Rizwan","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"C761","DOI":"10.1152\/ajpcell.00227.2008","article-title":"Probenecid, a gout remedy, inhibits pannexin 1 channels","volume":"295","author":"Silverman","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: A critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tox.2013.07.004","article-title":"Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates","volume":"311","author":"Janeba","year":"2013","journal-title":"Toxicology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jinf.2021.05.037","article-title":"Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"83","author":"Everts","year":"2021","journal-title":"J. Infect."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"105814","DOI":"10.1016\/j.ejps.2021.105814","article-title":"Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions","volume":"162","author":"Li","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e9628","DOI":"10.15252\/msb.20209628","article-title":"In vitro and in vivo identification of clinically approved drugs that modify ACE 2 expression","volume":"16","author":"Sinha","year":"2020","journal-title":"Mol. Syst. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"L121","DOI":"10.1152\/ajplung.00146.2020","article-title":"Consideration of Pannexin 1 channels in COVID-19 pathology and treatment","volume":"319","author":"Swayne","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.immuni.2021.06.014","article-title":"Pannexin 1 channels facilitate communication between T cells to restrict the severity of airway inflammation","volume":"54","author":"Medina","year":"2021","journal-title":"Immunity"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"103478","DOI":"10.1016\/j.isci.2021.103478","article-title":"Pannexin-1 channel opening is critical for COVID-19 pathogenesis","volume":"24","author":"Luu","year":"2021","journal-title":"iScience"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijmm.2014.05.002","article-title":"Probenecid reduces infection and inflammation in acute Pseudomonas aeruginosa pneumonia","volume":"304","author":"Wonnenberg","year":"2014","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1038\/sj.emboj.7601378","article-title":"Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor","volume":"25","author":"Pelegrin","year":"2006","journal-title":"EMBO J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","article-title":"Molecular physiology of P2X receptors","volume":"82","author":"North","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1111\/bph.14787","article-title":"Repurposing drugs targeting the P2X7 receptor to limit hyperinflammation and disease during influenza virus infection","volume":"176","author":"Rosli","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41590-021-01104-y","article-title":"Pathological sequelae of long-haul COVID","volume":"23","author":"Mehandru","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Weaver, A.K., Head, J.R., Gould, C.F., Carlton, E.J., and Remais, J.V. (2022). Environmental Factors Influencing COVID-19 Incidence and Severity. Annu. Rev. Public Health, 43.","DOI":"10.1146\/annurev-publhealth-052120-101420"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1242\/jcs.009514","article-title":"Pannexin 1 and pannexin 3 are glycoproteins that exhibit many distinct characteristics from the connexin family of gap junction proteins","volume":"120","author":"Penuela","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbamem.2017.03.004","article-title":"Transcriptional and post-translational regulation of pannexins","volume":"1860","author":"Boyce","year":"2018","journal-title":"Biochim. et Biophys. Acta (BBA) Biomembr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"104805","DOI":"10.1016\/j.antiviral.2020.104805","article-title":"Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors\u2019 responses","volume":"178","author":"Bray","year":"2020","journal-title":"Antivir. Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/3\/612\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:36:51Z","timestamp":1760135811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/3\/612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["v14030612"],"URL":"https:\/\/doi.org\/10.3390\/v14030612","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}